These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23333701)

  • 1. Positron emission tomography imaging of dopamine D2 receptors using a highly selective radiolabeled D2 receptor partial agonist.
    Xu J; Vangveravong S; Li S; Fan J; Jones LA; Cui J; Wang R; Tu Z; Chu W; Perlmutter JS; Mach RH
    Neuroimage; 2013 May; 71():168-74. PubMed ID: 23333701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous dopamine (DA) competes with the binding of a radiolabeled D₃ receptor partial agonist in vivo: a positron emission tomography study.
    Mach RH; Tu Z; Xu J; Li S; Jones LA; Taylor M; Luedtke RR; Derdeyn CP; Perlmutter JS; Mintun MA
    Synapse; 2011 Aug; 65(8):724-32. PubMed ID: 21132811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primates.
    Tóth M; Varrone A; Steiger C; Laszlovszky I; Horváth A; Kiss B; Gyertyán I; Adham N; Halldin C; Gulyás B
    Synapse; 2013 May; 67(5):258-64. PubMed ID: 23238770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography.
    Ginovart N; Galineau L; Willeit M; Mizrahi R; Bloomfield PM; Seeman P; Houle S; Kapur S; Wilson AA
    J Neurochem; 2006 May; 97(4):1089-103. PubMed ID: 16606355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA.
    Ito H; Takano H; Arakawa R; Takahashi H; Kodaka F; Takahata K; Nogami T; Suzuki M; Suhara T
    PLoS One; 2012; 7(9):e46488. PubMed ID: 23029533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of dopamine D₂/₃ specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹C]FLB 457: implications for measuring cortical dopamine release.
    Narendran R; Mason NS; Chen CM; Himes M; Keating P; May MA; Rabiner EA; Laruelle M; Mathis CA; Frankle WG
    Synapse; 2011 Oct; 65(10):991-7. PubMed ID: 21360596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA.
    Seneca N; Zoghbi SS; Skinbjerg M; Liow JS; Hong J; Sibley DR; Pike VW; Halldin C; Innis RB
    Synapse; 2008 Oct; 62(10):756-63. PubMed ID: 18651641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride.
    Seneca N; Finnema SJ; Farde L; Gulyás B; Wikström HV; Halldin C; Innis RB
    Synapse; 2006 Apr; 59(5):260-9. PubMed ID: 16416444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Separating dopamine D
    Smart K; Gallezot JD; Nabulsi N; Labaree D; Zheng MQ; Huang Y; Carson RE; Hillmer AT; Worhunsky PD
    Neuroimage; 2020 Jul; 214():116762. PubMed ID: 32201327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiosynthesis, ex vivo and in vivo evaluation of [11C]preclamol as a partial dopamine D2 agonist radioligand for positron emission tomography.
    Vasdev N; Natesan S; Galineau L; Garcia A; Stableford WT; McCormick P; Seeman P; Houle S; Wilson AA
    Synapse; 2006 Sep; 60(4):314-8. PubMed ID: 16786538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.
    Narendran R; Slifstein M; Guillin O; Hwang Y; Hwang DR; Scher E; Reeder S; Rabiner E; Laruelle M
    Synapse; 2006 Dec; 60(7):485-95. PubMed ID: 16952157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans.
    Shotbolt P; Tziortzi AC; Searle GE; Colasanti A; van der Aart J; Abanades S; Plisson C; Miller SR; Huiban M; Beaver JD; Gunn RN; Laruelle M; Rabiner EA
    J Cereb Blood Flow Metab; 2012 Jan; 32(1):127-36. PubMed ID: 21878947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rostrocaudal gradients of dopamine D2/3 receptor binding in striatal subregions measured with [(11)C]raclopride and high-resolution positron emission tomography.
    Alakurtti K; Johansson JJ; Tuokkola T; Någren K; Rinne JO
    Neuroimage; 2013 Nov; 82():252-9. PubMed ID: 23727314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography.
    Wilson AA; McCormick P; Kapur S; Willeit M; Garcia A; Hussey D; Houle S; Seeman P; Ginovart N
    J Med Chem; 2005 Jun; 48(12):4153-60. PubMed ID: 15943487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
    Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo [11C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro.
    McCormick PN; Kapur S; Reckless G; Wilson AA
    Synapse; 2009 Nov; 63(11):998-1009. PubMed ID: 19598174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The distribution of D2/D3 receptor binding in the adolescent rhesus monkey using small animal PET imaging.
    Christian BT; Vandehey NT; Fox AS; Murali D; Oakes TR; Converse AK; Nickles RJ; Shelton SE; Davidson RJ; Kalin NH
    Neuroimage; 2009 Feb; 44(4):1334-44. PubMed ID: 19015034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, [11C]RGH-1756 in the monkey brain.
    Sóvágó J; Farde L; Halldin C; Langer O; Laszlovszky I; Kiss B; Gulyás B
    Neurochem Int; 2004 Oct; 45(5):609-17. PubMed ID: 15234102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of the binding of dopamine D2/D3 receptor agonist, (R,S)-5-hydroxy-2-(N-propyl-N-(5'-(18)F-fluoropentyl)aminotetralin ((18)F-5-OH-FPPAT) in rodents and nonhuman primates.
    Shi B; Narayanan TK; Christian BT; Chattopadhyay S; Mukherjee J
    Nucl Med Biol; 2004 Apr; 31(3):303-11. PubMed ID: 15028242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.
    Graff-Guerrero A; Willeit M; Ginovart N; Mamo D; Mizrahi R; Rusjan P; Vitcu I; Seeman P; Wilson AA; Kapur S
    Hum Brain Mapp; 2008 Apr; 29(4):400-10. PubMed ID: 17497628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.